Related Experiment Video

Updated: Feb 4, 2026

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

15.0K

Population-based phase II trial of stereotactic ablative radiotherapy (SABR) for up to 5 oligometastases: SABR-5

Robert Olson1,2,3, Mitchell Liu4,5, Alanah Bergman5

  • 1University of British Columbia, Vancouver, Canada. rolson2@bccancer.bc.ca.

BMC Cancer
|October 6, 2018
PubMed
Abstract

Insights

This study assesses the toxicity of stereotactic ablative radiotherapy (SABR) for oligometastases, a limited cancer spread state. Findings will inform the safe use of SABR outside of clinical trials.

Area of Science:

  • Oncology
  • Radiation Oncology
  • Clinical Trials

Background:

  • Oligometastases represent a limited stage of cancer spread (1-5 metastases).
  • Stereotactic ablative radiotherapy (SABR) is an emerging treatment for oligometastases.
  • There is a need for prospective toxicity data for SABR in oligometastatic disease.

Purpose of the Study:

  • To evaluate the toxicity of SABR in patients with oligometastatic cancer.
  • To provide population-based toxicity estimates for SABR treatment.
  • To inform the off-trial use of SABR.

Main Methods:

  • A non-randomized, phase II clinical trial.
  • 200 patients with newly diagnosed or progressing oligometastatic disease will receive SABR.
  • The study is powered to estimate the risk of late grade 4 toxicity with 95% confidence.

Main Results:

  • This section is not available in the provided abstract.

Conclusions:

  • SABR is increasingly used for oligometastases off-trial without sufficient toxicity data.
  • This trial will yield crucial toxicity data for SABR in a population-based cohort.
  • Results will complement ongoing efficacy data from phase III trials.
Keywords:
OligometastasesRadiotherapyStereotactic ablative radiotherapy

More Related Videos

Determination of S-Phase Duration Using 5-Ethynyl-2'-deoxyuridine Incorporation in Saccharomyces cerevisiae08:40

Determination of S-Phase Duration Using 5-Ethynyl-2'-deoxyuridine Incorporation in Saccharomyces cerevisiae

Published on: October 21, 2022

1.9K
Immunohistochemical Detection of 5-Methylcytosine and 5-Hydroxymethylcytosine in Developing and Postmitotic Mouse Retina07:50

Immunohistochemical Detection of 5-Methylcytosine and 5-Hydroxymethylcytosine in Developing and Postmitotic Mouse Retina

Published on: August 29, 2018

9.5K

Related Concept Videos

5-Number Summary01:04

5-Number Summary

In a dataset, the 5-number summary includes the minimum data value, the data value of the first quartile, the median data value or data value of the second quartile, the data value of the third quartile, and the maximum data value. These 5 data values can be visualized as a box and whisker plot.
In a box plot, the minimum and maximum data values represent the lower and upper whiskers in the graph, and the median is designated as the center of the box in the chart. The first quartile and third...
5.7K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
669
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.0K
Trial and Error and Algorithm01:12

Trial and Error and Algorithm

A problem-solving strategy is a plan of action used to find a solution. Different strategies have distinct action plans. Trial and error involves trying different solutions until one works. For instance, to fix a broken printer, you might check ink levels, ensure the paper tray isn't jammed, and verify the printer's connection to your laptop. This method can be time-consuming but is commonly used. Thomas Edison, for example, used trial and error to find a suitable filament for the light...
424
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
10.7K
Conservation of Small Populations02:04

Conservation of Small Populations

Small population sizes put a species at extreme risk of extinction due to a lack of variation, and a consequent decrease in adaptability. This weakens the chances of survival under pressures such as climate change, competition from other species, or new diseases. Large populations are more likely to survive pressures such as these, as such populations are more likely to harbor individuals that have genetic variants that are adaptive under new stresses. Small populations are much less...
17.4K